| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
beta-Amyloid (35-42) itself does not have a defined pharmacological target; rather, it serves as a model peptide for studying amyloid-beta aggregation, fibril formation, and protein misfolding pathways relevant to Alzheimer's disease pathology.
|
|---|---|
| ln Vitro |
Beta-Amyloid Aggregation Guidelines: The protocol we recommend is as follows. You should adjust this process to suit your unique needs as it simply offers guidelines. Dissolve the solid Aβ peptide in cold HFIP (hexafluoro-2-propanol). To ensure that the structure is randomized and monomerized, incubate the peptides for a minimum of one hour at room temperature. 2. Put the peptide that results from evaporating to preserve it on a film at -20 or -80°C. This will eliminate HFIP. 3. After achieving the desired concentration and buffer (serum- and phenol-red-free media), dissolve the resultant membrane in anhydrous DMSO at a concentration of 5 mM, vortex, and dilute. The solution should then be aged for 48 hours at 4–8°C. The supernatant contained soluble oligomers after the samples were centrifuged for 10 minutes at 4–8°C at 14,000 g. 10–200 times washed supernatant was used in studies. The techniques used differ based on the final use.
In vitro, beta-Amyloid (35-42) is used to study the kinetics of amyloid fibril formation and aggregation. The peptide can form oligomers and fibrils under appropriate conditions, which are analyzed using Thioflavin T fluorescence, electron microscopy, or circular dichroism spectroscopy to monitor conformational changes from random coil to beta-sheet structure. |
| ln Vivo |
In vivo, beta-Amyloid (35-42) has been utilized in animal models of Alzheimer's disease to investigate amyloid-induced neurotoxicity and cognitive impairment. The peptide can be injected intracerebroventricularly to induce amyloid plaque formation and memory deficits in rodents, serving as a tool to evaluate potential therapeutic interventions.
|
| Enzyme Assay |
For non-cellular enzyme/receptor binding assays, beta-Amyloid (35-42) aggregation studies typically involve dissolving the peptide in hexafluoro-2-propanol (HFIP) to establish monomerization, followed by solvent evaporation and storage as a film at -20degC or -80degC. The film is then dissolved in anhydrous DMSO at 5 mM and diluted into appropriate buffer, aged at 4-8degC for 48 hours, and centrifuged at 14,000 g for 10 minutes to collect soluble oligomers in the supernatant.
|
| Cell Assay |
For in vitro cellular assays, the aggregated beta-Amyloid (35-42) oligomers prepared from the supernatant are diluted 10- to 200-fold and applied to neuronal cell cultures such as SH-SY5Y or primary cortical neurons. Cytotoxicity is typically assessed via MTT or LDH release assays, while oxidative stress markers and apoptosis pathways are evaluated to study amyloid-induced neurotoxicity.
|
| Animal Protocol |
In vivo animal experiments with beta-Amyloid (35-42) typically involve intracerebroventricular injection of aggregated peptide into rodent models (e.g., mice or rats). Following peptide administration, cognitive function is assessed using Morris water maze or novel object recognition tests. Brain tissues are subsequently harvested for histological analysis of amyloid plaque deposition, neuronal loss, and glial activation.
|
| ADME/Pharmacokinetics |
As a research peptide, beta-Amyloid (35-42) is not developed as a therapeutic drug; therefore, systematic pharmacokinetic data are not available. For laboratory use, the peptide is typically administered via intracerebroventricular injection for localized brain exposure rather than systemic delivery.
|
| Toxicity/Toxicokinetics |
Toxicity data for beta-Amyloid (35-42) are primarily derived from in vitro neurotoxicity assays and in vivo studies, where high concentrations of aggregated amyloid peptides induce neuronal cell death, oxidative stress, and inflammatory responses. The peptide itself is not intended for therapeutic use and is classified as a research reagent only.
|
| References | |
| Additional Infomation |
beta-Amyloid (35-42) is a research-use-only peptide (CAS#: 183292-41-3) with molecular formula C33H₆0N₈O₉S and molecular weight 744.94. It is supplied as a white to off-white solid and should be stored sealed, away from moisture, at -80degC for up to 2 years. The peptide sequence is Met-Val-Gly-Gly-Val-Val-Ile-Ala.
|
| Molecular Formula |
C33H60N8O9S
|
|---|---|
| Molecular Weight |
744.942707061768
|
| Exact Mass |
744.42
|
| CAS # |
183292-41-3
|
| PubChem CID |
25184743
|
| Appearance |
White to off-white solid powder
|
| LogP |
-0.7
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
51
|
| Complexity |
1220
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
[C@H]([C@@H](C)CC)(C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCSC
|
| InChi Key |
WMASSBNUXWFHBX-CMCOHCKLSA-N
|
| InChi Code |
InChI=1S/C33H60N8O9S/c1-11-19(8)27(32(48)37-20(9)33(49)50)41-31(47)26(18(6)7)40-30(46)25(17(4)5)38-23(43)15-35-22(42)14-36-29(45)24(16(2)3)39-28(44)21(34)12-13-51-10/h16-21,24-27H,11-15,34H2,1-10H3,(H,35,42)(H,36,45)(H,37,48)(H,38,43)(H,39,44)(H,40,46)(H,41,47)(H,49,50)/t19-,20-,21-,24-,25-,26-,27-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results. (2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~67.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.36 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3424 mL | 6.7119 mL | 13.4239 mL | |
| 5 mM | 0.2685 mL | 1.3424 mL | 2.6848 mL | |
| 10 mM | 0.1342 mL | 0.6712 mL | 1.3424 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
